DEA Inspects Medical Cannabis Applicants
DEA regional offices inspect medical cannabis applicants after rescheduling; they request ownership records, SOPs, security plans, and accept Form 225.
Tag: DEA
DEA Ends cannabis rescheduling Hearing; Record Grows
DEA hearing ends after 11 days; opponents compile evidence on youth exposure, product variability and diversion as agencies consider cannabis rescheduling;
Alabama panel hears medical marijuana rescheduling
Alabama health committee holds public hearing on medical marijuana rescheduling after DEA moved some FDA-approved products to Schedule III; comments due
Senator Presses AG on cannabis rescheduling
Acting AG won’t expand cannabis rescheduling; MA ballot initiative will appear in November; Fetterman urges legalization; NFL study reports athlete
DEA Hearing Tests cannabis rescheduling Proposal
DEA hearing on cannabis rescheduling draws seven opposition groups; FDA witness defends 252-page HHS analysis, two-part CAMU test, and 2023 recommendation.
DOJ Order Leaves tribal cannabis Programs Out
DOJ moved FDA-approved medical cannabis to Schedule III but omitted tribal cannabis programs, leaving questions on DEA registration, supply and tax policy.
medical cannabis shifts toward FDA-style pharmacy care
medical cannabis operators must adopt pharmacy-style GMP/GDP controls, HIPAA-grade records and clinician training after DOJ reschedules to Schedule 3.
cannabis rescheduling draws business intervention
Cannabis rescheduling prompts two companies to intervene in federal lawsuits; Congress files IBOGAINE Act; states update zoning and medical cannabis access.
Connecticut firms await marijuana rescheduling decision
marijuana rescheduling after a federal hearing leaves Connecticut cannabis operators awaiting DEA, IRS and bank actions that could change taxes, banking
Opponents Outline Case in marijuana rescheduling Hearing
Opponents present witnesses and evidence at DEA hearing on marijuana rescheduling, starting June 29 and running through July 15; DEA bars supporters and